Market Cap : 22.71 B | Enterprise Value : 22.99 B | PE Ratio : 62.48 | PB Ratio : 4.46 |
---|
HZNP has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
HZNP has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Horizon Therapeutics's EBITDA for the three months ended in Mar. 2023 was $130 Mil. Its EBITDA for the trailing twelve months (TTM) ended in Mar. 2023 was $842 Mil.
During the past 12 months, the average EBITDA Growth Rate of Horizon Therapeutics was -33.90% per year. During the past 3 years, the average EBITDA Growth Rate was 48.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.
During the past 13 years, the highest 3-Year average EBITDA Growth Rate of Horizon Therapeutics was 56.30% per year. The lowest was -80.60% per year. And the median was 28.90% per year.
Horizon Therapeutics's EBITDA per Share for the three months ended in Mar. 2023 was $0.55. Its EBITDA per share for the trailing twelve months (TTM) ended in Mar. 2023 was $3.59.
During the past 12 months, the average EBITDA per Share Growth Rate of Horizon Therapeutics was -33.50% per year. During the past 3 years, the average EBITDA per Share Growth Rate was 42.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per share growth rate using EBITDA per Share data.
During the past 13 years, the highest 3-Year average EBITDA per Share Growth Rate of Horizon Therapeutics was 64.80% per year. The lowest was 10.10% per year. And the median was 42.90% per year.
The historical data trend for Horizon Therapeutics's EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Horizon Therapeutics's EBITDA, along with its competitors' market caps and EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Horizon Therapeutics's EBITDA distribution charts can be found below:
* The bar in red indicates where Horizon Therapeutics's EBITDA falls in comparison to its industry or sector. The grey bar indicates the EBITDA's extreme value range as defined by GuruFocus.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Horizon Therapeutics's EBITDA for the fiscal year that ended in Dec. 2022 is calculated as
Horizon Therapeutics's EBITDA was directly provided by GuruFocus' data source Morningstar. For the fiscal year ended in Dec. 2022, Horizon Therapeutics's EBITDA was $1,001 Mil.
Horizon Therapeutics's EBITDA for the quarter that ended in Mar. 2023 is calculated as
Horizon Therapeutics's EBITDA was directly provided by GuruFocus' data source Morningstar. For the quarter ended in Mar. 2023, Horizon Therapeutics's EBITDA was $130 Mil.
EBITDA for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $842 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sometimes companies may have already deducted Depreciation and Amortization from Gross Profit. In this case Depreciation and Amortization needs to be added back when calculating EBITDA.
EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals Operating Income. Operating Income is profit before interest and taxes. Of course, Interest and taxes need to be paid.
While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.
The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.
EBITDA can be thought of as the cash a business generates that is available to:
Add more inventoryEBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses.. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.
A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.
Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.
Although depreciation is not a cash cost it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.
EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies. Also Price-to-EBITDA is sometimes used in valuations.
Thank you for viewing the detailed overview of Horizon Therapeutics's EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Patrick Mcilvenny | officer: Chief Accounting Officer | C/O HORIZON THERAPEUTICS PLC, 70 ST. STEPHEN'S GREEN, DUBLIN L2 D02 E2X4 |
Jacopo Leonardi | officer: Chief Commercial Officer | C/O HORIZON THERAPEUTICS PLC, 70 ST. STEPHEN'S GREEN, DUBLIN L2 D02 E2X4 |
Aaron Cox | officer: EVP, Chief Financial Officer | C/O HORIZON THERAPEUTICS PLC, 70 ST. STEPHEN'S GREEN, DUBLIN L2 D02 E2X4 |
Sean M. Clayton | officer: EVP, General Counsel | C/O HORIZON THERAPEUTICS PLC, 70 SAINT STEPHENS GREEN, DUBLIN L2 D02 E2X4 |
Thompson Elizabeth H.z. | officer: EVP, Research & Development | C/O HORIZON THERAPEUTICS, INC., 2 TOWER PLACE, 12TH FLOOR, SOUTH SAN FRANCISCO CA 94080 |
Karin Rosen | officer: EVP, R&D & CSO | C/O HORIZON THERAPEUTICS, INC., CONNAUGHT HOUSE, 1ST FL, 1 BURLINGTON RD, DUBLIN L2 D04 C5Y6 |
Daniel A. Camardo | officer: EVP and President, U.S. | ATHERSYS, INC., 3201 CARNEGIE AVE, CLEVELAND OH 44115 |
Andy Pasternak | officer: EVP and Chief Business Officer | C/O HORIZON THERAPEUTICS PLC, CONNAUGHT HOUSE, 1ST FL, 1 BURLINGTON RD, DUBLIN L2 D04 C5Y6 |
Susan Mahony | director | LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285 |
Jeff Kent | officer: See remarks | C/O HORIZON PHARMA PLC, CONNAUGHT HOUSE, 1ST FL, 1 BURLINGTON RD, DUBLIN L2 4 |
Shao-lee Lin | officer: EVP, Head of R&D and CSO | C/O HORIZON PHARMA PLC, CONNAUGHT HOUSE, 1ST FL, 1 BURLINGTON RD, DUBLIN L2 4 |
Irina Konstantinovsky | officer: EVP, Chief Human Resources Off | C/O HORIZON PHARMA PLC, CONNAUGHT HOUSE, 1ST FL, 1 BURLINGTON RD, DUBLIN L2 4 |
Eric Mosbrooker | officer: SVP, Orphan Business Unit | C/O HORIZON PHARMA, PLC, ADELAIDE CHAMBERS, PETER STREET, DUBLIN 8 L2 000000 |
Pascale Witz | director | C/O REGULUS THERAPEUTICS INC., 10614 SCIENCE CENTER DRIVE, SAN DIEGO CA 92121 |
James Samuel Shannon | director | 28903 NORTH AVENUE PAINE, VALENCIA CA 91355 |
From GuruFocus
By Stock market mentor 01-25-2023
By Business Wire 12-20-2022
By Business Wire 12-12-2022
Other Sources
By Seekingalpha 2023-01-12
By Yahoo Finance 2023-01-17
By Yahoo Finance 2022-12-20
By Zacks 2023-01-19
By Bloomberg 2023-01-30
By Zacks 2023-01-12
By Yahoo Finance 2023-01-30
By Bloomberg 2022-12-21
By Zacks 2023-01-25
By Yahoo Finance 2022-11-30
By Yahoo Finance 2023-01-03
By Yahoo Finance 2022-11-30
By Yahoo Finance 2023-01-04
By Reuters 2023-01-31
By Yahoo Finance 2023-01-23